Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to ...

Great things were expected of Allogene Therapeutics’ IPO this week – the company is led by Arie Belldegrun and David Chang, who masterminded development and approval of Kite Pharma’s CAR-T ...

Led by former Kite execs Arie Belldegrun and David Chang, Allogene partnered with French firms Cellectis and Servier to develop allogeneic CAR-Ts, after buying out Pfizer and taking over its role ...

William Blair analyst Sami Corwin has reiterated their bullish stance on ALLO stock, giving a Buy rating on November 11. Sami Corwin has given ...

Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target ...

Q3 2024 Earnings Call Transcript November 7, 2024 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

David Chang, President and Chief Executive Officer ... to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements.

L Consolidation Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Continuing with Site Activation and Patient ...

and the first CD19/CD70 dual CAR T candidate specifically designed for autoimmune disease,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene.

Allogene Therapeutics ... Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.